# OnCo record bi-1607 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bi-1607/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bi-1607" ;
  schema:name "BI-1607"@en ;
  schema:description "BI-1607 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for melanoma, uveal melanoma and HER2-positive breast cancer and other cancers."@en ;
  schema:url <https://onco.cc/drugs/bi-1607/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1607>, <https://www.bioinvent.com/en>, <https://clinicaltrials.gov/search?intr=BI-1607> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Monoclonal antibody (engineered)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/uveal-melanoma/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/gastric-her2-positive/> ;
  onco:targets <https://onco.cc/targets/fcgr2b/> ;
  onco:companies <https://onco.cc/companies/bioinvent-international/> ;
  onco:trials <https://onco.cc/trials/nct06784648/>, <https://onco.cc/trials/nct05555251/> .